| Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings | As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application... ► Artikel lesen |
| Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity | Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic- and Wegovy- Combining ART27.13... ► Artikel lesen |
| Artelo Biosciences Announces Reverse Stock Split | SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling... ► Artikel lesen |
| Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen |
| Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen |
| Krebs-Blockbuster-Medikament: Revolution Medicines: Auch Europa will das Medikament so schnell wie möglich! | © Foto: KI-generiert mit DALL-ENach starken Studiendaten aus den USA will nach der FDA auch Europas Arzneimittelbehörde das Medikament so schnell wie möglich zulassen. Revolution Medicines wird immer... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results | FDA accepted the new drug application (NDA) for ulixacaltamide in Essential Tremor with a PDUFA target action date of January 29, 2027, and the NDA for relutrigine, with priority review, in SCN2A... ► Artikel lesen |